Tuesday, April 28, 2026, 12:00 PM–1:00 PM ET
Discover how next-day comprehensive genomic profiling (CGP) is possible with the Oncomine Comprehensive Assay Plus on the Genexus System—delivering both speed and accuracy.
Webinar presenters Jane Bayani, MHSc, PhD, Assistant Professor and Co-Director, Diagnostic Development, Ontario Institute for Cancer Research, Canada, and Nicola Normanno, MD, Scientific Director, IRCCS Romagnolo Institute for the Study of Tumors, Italy, and Morten Grauslund, PhD, Molecular Biologist, Department of Pathology, Rigshospitalet/Copenhagen University Hospital, Copenhagen, Denmark.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Thermo Fisher Scientific. For Research Use Only. Not for use in diagnostic applications.
Thursday, April 30, 2026, 11:00 AM–12:00 PM ET
Hear an expert discuss how Memorial Sloan Kettering Cancer Center (MSKCC) is utilizing
the oncoReveal® Nexus 21-gene panel to redefine turnaround time and actionable insights
in cancer care. Dr. Ewalt shares a perceptive look at the clinical need for rapid, front-line NGS sequencing, and how a unique, purpose built targeted NGS panel (Pillar Biosciences’ oncoReveal Nexus 21 gene Panel) was developed, validated and implemented clinically by Memorial Sloan Kettering Cancer Center (MSK-REACT) to complement their current comprehensive genomic profiling (CGP) approach.
Webinar presenter Mark Ewalt, MD, Associate Medical Director for Laboratory Operations for Diagnostic Molecular Pathology in the Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, MSKCC.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Pillar Biosciences.
Thursday, May 28, 2026, 1:00–2:00 PM ET
This session is designed to improve understanding and application of recent updates to synoptic pathology reporting protocols such as the latest Reporting Template for Reporting Results of Biomarker Testing of Specimens from Patients with Carcinoma of the Breast. These changes reflect evolving clinical guidelines that directly influence diagnostic accuracy and treatment selection in breast cancer care.
Webinar presenters Thaer Khoury, MD, FCAP, Chair, Pathology and Laboratory Medicine, Roswell Park Comprehensive Cancer Cente, and Colin Murphy, CEO of mTuitive.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
March 12, 2026—The FDA has granted breakthrough device designation to MeMed’s BV Flex, a blood test designed to distinguish between bacterial and viral infections based on the body’s immune response.
March 11, 2026—Biocartis’ Idylla CDx MSI test has received class C companion diagnostic certification under the European Union IVDR.
March 9, 2026—Agilent Technologies has entered into a definitive agreement to acquire Biocare Medical in an all-cash transaction valued at $950 million.
March 4, 2026—A new report from KLAS Research awarded Proscia the highest overall performance score (95.2) in the U.S. market, based on customer feedback.
Feb. 26, 2026—ARUP Laboratories has launched the Innovation Central Laboratory to facilitate collaboration with pharmaceutical, biotechnology, and other industry partners.
Feb. 25, 2026—Labcorp is expanding its collaboration with PathAI to deploy PathAI’s AISight Dx, an FDA-cleared digital pathology platform, across its anatomic pathology labs and hospital collaborations.
Feb. 24, 2026—Exa Capital has acquired StaffReady, an SaaS platform for managing clinical workforces in health care.
Feb. 23, 2026—Copan Group’s PhenoMatrix, an automated image assessment software used with the company’s WASPLab laboratory automation platform, received FDA 510(k) clearance as a class II device.
Feb. 20, 2026—Arlington Scientific has completed its acquisition of Awareness Technology’s EIA/ELISA product line.
Feb. 19, 2026—The American Board of Pathology is updating how diplomate status will be recorded for people no longer in active practice.
